Cargando…

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors

PURPOSE: We performed a pilot study to determine the benefit of high-dose chemotherapy and autologous peripheral blood stem cell transplantation (HDCT/autoPBSCT) for patients with Ewing sarcoma family of tumors. METHODS: We retrospectively analyzed the data of patients who received HDCT/autoPBSCT at...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Juhee, Kim, Dong Ho, Lim, Jung Sub, Koh, Jae-Soo, Yoo, Ji Young, Kong, Chang-Bae, Song, Won Seok, Cho, Wan Hyeong, Jeon, Dae-Geun, Lee, Soo-Yong, Lee, Jun Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Pediatric Society 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819677/
https://www.ncbi.nlm.nih.gov/pubmed/24223602
http://dx.doi.org/10.3345/kjp.2013.56.9.401
_version_ 1782290020052238336
author Seo, Juhee
Kim, Dong Ho
Lim, Jung Sub
Koh, Jae-Soo
Yoo, Ji Young
Kong, Chang-Bae
Song, Won Seok
Cho, Wan Hyeong
Jeon, Dae-Geun
Lee, Soo-Yong
Lee, Jun Ah
author_facet Seo, Juhee
Kim, Dong Ho
Lim, Jung Sub
Koh, Jae-Soo
Yoo, Ji Young
Kong, Chang-Bae
Song, Won Seok
Cho, Wan Hyeong
Jeon, Dae-Geun
Lee, Soo-Yong
Lee, Jun Ah
author_sort Seo, Juhee
collection PubMed
description PURPOSE: We performed a pilot study to determine the benefit of high-dose chemotherapy and autologous peripheral blood stem cell transplantation (HDCT/autoPBSCT) for patients with Ewing sarcoma family of tumors. METHODS: We retrospectively analyzed the data of patients who received HDCT/autoPBSCT at Korea Cancer Center Hospital. Patients with relapsed, metastatic, or centrally located tumors were eligible for the study. RESULTS: A total of 9 patients (3 male, 6 female), with a median age at HDCT/autoPBSCT of 13.4 years (range, 7.1 to 28.2 years), were included in this study. Patients underwent conventional chemotherapy and local control either by surgery or radiation therapy, and had achieved complete response (CR, n=7), partial response (n=1), or stable disease (n=1) prior to HDCT/autoPBSCT. There was no transplant-related mortality. However, the median duration of overall survival and event-free survival after HDCT/autoPBSCT were 13.3 months (range, 5.3 to 44.5 months) and 6.2 months (range, 2.1 to 44.5 months), respectively. At present, 4 patients are alive and 5 patients who experienced adverse events (2 metastasis, 2 local recur, and 1 progressive disease) survived for a median time of 2.8 months (range, 0.1 to 10.7 months). The 2-year survival after HDCT/autoPBSCT was 44.4%±16.6% and disease status at the time of HDCT/autoPBSCT tended to influence survival (57.1%±18.7% of cases with CR vs. 0% of cases with non-CR, P=0.07). CONCLUSION: Disease status at HDCT/autoPBSCT tended to influence survival. Further studies are necessary to define the role of HDCT/autoPBSCT and to identify subgroup of patients who might benefit from this investigational treatment.
format Online
Article
Text
id pubmed-3819677
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The Korean Pediatric Society
record_format MEDLINE/PubMed
spelling pubmed-38196772013-11-09 High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors Seo, Juhee Kim, Dong Ho Lim, Jung Sub Koh, Jae-Soo Yoo, Ji Young Kong, Chang-Bae Song, Won Seok Cho, Wan Hyeong Jeon, Dae-Geun Lee, Soo-Yong Lee, Jun Ah Korean J Pediatr Original Article PURPOSE: We performed a pilot study to determine the benefit of high-dose chemotherapy and autologous peripheral blood stem cell transplantation (HDCT/autoPBSCT) for patients with Ewing sarcoma family of tumors. METHODS: We retrospectively analyzed the data of patients who received HDCT/autoPBSCT at Korea Cancer Center Hospital. Patients with relapsed, metastatic, or centrally located tumors were eligible for the study. RESULTS: A total of 9 patients (3 male, 6 female), with a median age at HDCT/autoPBSCT of 13.4 years (range, 7.1 to 28.2 years), were included in this study. Patients underwent conventional chemotherapy and local control either by surgery or radiation therapy, and had achieved complete response (CR, n=7), partial response (n=1), or stable disease (n=1) prior to HDCT/autoPBSCT. There was no transplant-related mortality. However, the median duration of overall survival and event-free survival after HDCT/autoPBSCT were 13.3 months (range, 5.3 to 44.5 months) and 6.2 months (range, 2.1 to 44.5 months), respectively. At present, 4 patients are alive and 5 patients who experienced adverse events (2 metastasis, 2 local recur, and 1 progressive disease) survived for a median time of 2.8 months (range, 0.1 to 10.7 months). The 2-year survival after HDCT/autoPBSCT was 44.4%±16.6% and disease status at the time of HDCT/autoPBSCT tended to influence survival (57.1%±18.7% of cases with CR vs. 0% of cases with non-CR, P=0.07). CONCLUSION: Disease status at HDCT/autoPBSCT tended to influence survival. Further studies are necessary to define the role of HDCT/autoPBSCT and to identify subgroup of patients who might benefit from this investigational treatment. The Korean Pediatric Society 2013-09 2013-09-30 /pmc/articles/PMC3819677/ /pubmed/24223602 http://dx.doi.org/10.3345/kjp.2013.56.9.401 Text en Copyright © 2013 by The Korean Pediatric Society http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Seo, Juhee
Kim, Dong Ho
Lim, Jung Sub
Koh, Jae-Soo
Yoo, Ji Young
Kong, Chang-Bae
Song, Won Seok
Cho, Wan Hyeong
Jeon, Dae-Geun
Lee, Soo-Yong
Lee, Jun Ah
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors
title High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors
title_full High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors
title_fullStr High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors
title_full_unstemmed High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors
title_short High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors
title_sort high-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with ewing sarcoma family of tumors
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819677/
https://www.ncbi.nlm.nih.gov/pubmed/24223602
http://dx.doi.org/10.3345/kjp.2013.56.9.401
work_keys_str_mv AT seojuhee highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT kimdongho highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT limjungsub highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT kohjaesoo highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT yoojiyoung highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT kongchangbae highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT songwonseok highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT chowanhyeong highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT jeondaegeun highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT leesooyong highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors
AT leejunah highdosechemotherapyandautologousperipheralbloodstemcelltransplantationinthetreatmentofchildrenandadolescentswithewingsarcomafamilyoftumors